Header
For Healthcare Professionals

Overview do nosso pipeline

A área de Oncologia é a prioridade número 1 de pesquisa e desenvolvimento da Boehringer Ingelheim. Temos 6 centros de pesquisa focados em Oncologia nos Estados Unidos e na Europa. São mais de 500 cientistas dedicados ao desenvolvimento de novas terapias-alvo, estratégias inovadoras de imuno-oncologia e abordagens de combinação inteligente que podem transformar a vida dos pacientes

Our-Pipeline
Download Pipeline PDF
Molécula e alvo LATEST DEVELOPMENT PHASE (AS OF MARCH 2022)
Fase I Fase II
Cancer cell-directed and immuno-oncology terapias
Antagonista MDM2-p52 PHASE II TUMORES SÓLIDOS CANCER CELL-DIRECTED THERAPIES, CELL DEATH/APOPTOSIS, PROTEIN::PROTEIN INTERACTION, IMMUNO-ONCOLOGY THERAPIES, CELL DEATH/APOPTOSIS

Tumores sólidos
Inibidor pan-KRAS SOS1 PHASE I TUMORES SÓLIDOS CANCER CELL-DIRECTED THERAPIES, PROLIFERATION AND SURVIVAL, PROTEIN::PROTEIN INTERACTION

Tumores sólidos
Inibidor KRAS G12C PHASE I TUMORES SÓLIDOS CANCER CELL-DIRECTED THERAPIES, PROLIFERATION AND SURVIVAL, RAS/RAF/MEK/ERK SIGNALLING

Tumores sólidos
Inibidor MEK PHASE I TUMORES SÓLIDOS CANCER CELL-DIRECTED THERAPIES, PROLIFERATION AND SURVIVAL, RAS/RAF/MEK/ERK SIGNALLING

Tumores sólidos
Anticorpo TRAILR2/CDH17 PHASE I GASTROINTESTINAL CANCER CANCER CELL-DIRECTED THERAPIES, CELL DEATH/APOPTOSIS

Cancer gastrointestinal
Anticorpo conjugado à droga (ACD) ROR1 PHASE I TUMORES SÓLIDOS CANCER CELL-DIRECTED THERAPIES, CELL DEATH/APOPTOSIS

Tumores sólidos
Inibidor HER2 exon 20 PHASE I TUMORES SÓLIDOS CANCER CELL-DIRECTED THERAPIES, ERBB SIGNALLING, PROLIFERATION AND SURVIVAL

Tumores sólidos
Ezabenlimabe PHASE I TUMORES SÓLIDOS IMMUNO-ONCOLOGY THERAPIES, CHECKPOINT INHIBITION

Tumores sólidos
Antagonista SIRP (alfa) PHASE I TUMORES SÓLIDOS IMMUNO-ONCOLOGY THERAPIES, CHECKPOINT INHIBITION

Tumores sólidos
Anticorpo agonista biespecífico CD137/FAP PHASE I TUMORES SÓLIDOS

Tumores sólidos
Vacina KISIMA TM (ATP-128) PHASE I COLORECTAL CANCER IMMUNO-ONCOLOGY THERAPIES, ADAPTIVE IMMUNITY, CANCER VACCINES

CCR
VSV-GP PHASE I TUMORES SÓLIDOS

Tumores sólidos
Ativador de célula T DLL3/CD3 PHASE I SMALL CELL LUNG CANCER, NEUROENDOCRINE TUMORS IMMUNO-ONCOLOGY THERAPIES, ADAPTIVE IMMUNITY

TNE

CPPC
Ativador de célula T B7-H6/CD3 PHASE I TUMORES SÓLIDOS IMMUNO-ONCOLOGY THERAPIES, ADAPTIVE IMMUNITY

Tumores sólidos
Agonista STING PHASE I TUMORES SÓLIDOS IMMUNO-ONCOLOGY THERAPIES, INNATE IMMUNITY

Tumores sólidos
Combination Approaches
Antagonista MDM2-p53 + ezabenlimabe PHASE I TUMORES SÓLIDOS

Tumores sólidos
Antagonista SIRP(alfa) + ezabenlimabe PHASE I TUMORES SÓLIDOS

Tumores sólidos
Vacina KISIMA TM (ATP-128) + ezabenlimabe PHASE I COLORECTAL CANCER

CCR
Ativador de célula T DLL3/CD3 + ezabenlimabe PHASE I SMALL CELL LUNG CANCER, NEUROENDOCRINE TUMORS

TNE

CPPC
Ativador de célula T B7-H6/CD3 + ezabenlimabe PHASE I TUMORES SÓLIDOS

Tumores sólidos
Agonista STING + ezabenlimab PHASE I TUMORES SÓLIDOS

Tumores sólidos
Download Pipeline PDF

  1. ClinicalTrials.gov. NCT05218499. https://clinicaltrials.gov/ct2/show/NCT05218499 (Accessed: February 2022)

  2. ClinicalTrials.gov. NCT04111458. https://clinicaltrials.gov/ct2/show/NCT04111458 (Accessed: February 2022)

  3. ClinicalTrials.gov. NCT04973163. https://clinicaltrials.gov/ct2/show/NCT04973163 (Accessed: February 2022)

  4. ClinicalTrials.gov. NCT04742556. http://clinicaltrials.gov/ct2/show/NCT04742556 (Accessed: February 2022)

  5. ClinicalTrials.gov. NCT04137289. https://clinicaltrials.gov/ct2/show/NCT04137289 (Accessed: February 2022)

  6. ClinicalTrials.gov. NCT04441099. http://clinicaltrials.gov/ct2/show/NCT04441099 (Accessed: February 2022)

  7. ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/ct2/show/NCT04886804 (Accessed: February 2022)

  8. ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/ct2/show/NCT03697304 (Accessed: February 2022)

  9. ClinicalTrials.gov. NCT02952248. http://clinicaltrials.gov/ct2/show/NCT02952248 (Accessed: February 2022)

  10. ClinicalTrials.gov. NCT03990233. https://clinicaltrials.gov/ct2/show/NCT03990233 (Accessed: February 2022)

  11. ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/ct2/show/NCT04958239 (Accessed: February 2022)

  12. ClinicalTrials.gov. NCT04046445. https://clinicaltrials.gov/ct2/show/NCT04046445 (Accessed: February 2022)

  13. ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/ct2/show/NCT04429087 (Accessed: February 2022)

  14. ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/ct2/show/NCT04752215 (Accessed: February 2022)

  15. ClinicalTrials.gov. NCT04147234. https://clinicaltrials.gov/ct2/show/NCT04147234 (Accessed: February 2022)

  16. ClinicalTrials.gov. NCT03964233. https://clinicaltrials.gov/ct2/show/NCT03964233 (Accessed: February 2022)

  17. ClinicalTrials.gov. NCT04835714. https://clinicaltrials.gov/ct2/show/NCT04835714 (Accessed: February 2022)

  18. ClinicalTrials.gov. NCT04627142. https://clinicaltrials.gov/ct2/show/NCT04627142 (Accessed: February 2022)

Pipeline compounds shown here are under preclinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

ADC, antibody-drug conjugate; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; DLL3, Delta-like 3; FAP, fibroblast activation protein; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; LRP, lipoprotein receptor-related protein; MDM2, murine double minute 2 protein; MEK, mitogen-activated extracellular signal regulated kinase; NSCLC, non-small-cell lung cancer; NET, neuroendocrine tumor; ROR1, receptor tyrosine kinase-like orphan receptor 1; SCLC, small-cell lung cancer; SIRPα, signal-regulatory protein alpha; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VSV, vesicular stomatitis virus.